Please assess the completion status of the following clinical trial:

Trial Title: Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
1. Male aged 21 years or older.~2. Ability to provide signed informed consent and willingness to comply with protocol requirements.~3. Pathologic confirmation of adenocarcinoma of the prostate gland or high clinical suspicion (PSA \> 4 ng/mL, or PSA density \> 0.15 ng/mL2, or PSA doubling time \< 2 years).~4. Meet one of the following 5 criteria~   1. Planned for surgical extirpation, which may or may not include lymph node dissection (high risk primary disease)~  2. Planned for targeted biopsy of primary lesion~  3. Conventional imaging equivocal or suggestive of prostate cancer metastasis/es~  4. Planned focal therapy (with or without radiation therapy) with serial follow-up~  5. Elevated PSA with no conventional imaging suggestive of metastatic or recurrent disease~5. a. If part of PET/MRI cohort, subject will undergo clinically indicated MRI imaging prior to treatment.~   Or b. If part of PET/CT cohort, subject will have had clinically indicated MRI within 3 months prior to treatment.~6. Participants must agree to use an acceptable form of birth control throughout the study period. Participants must use condoms for a period of seven days after each injection, if engaged in sexual activity.~Exclusion Criteria:~1. Clinical and/or technical factors that would compromise statistical analysis of the PET and/or MRI.~2. If part of PET/MRI cohort and patient cohort 3 or 5, subject does not plan to have a prescribed abdomen and pelvis MRI~3. If part of PET/MRI cohort and patient cohort 1, 2 or 4, subject does not plan to have a prescribed pelvis MRI~4. If part of PET/CT cohort and patient cohort 3 or 5, subject does not have previous MR imaging of abdomen and pelvis~5. If part of PET/CT cohort and patient cohort 1, 2 or 4, subject does not have previous MR imaging of pelvis~6. If part of PET/CT cohort, investigator review determines that previous MR images do not meet institutional quality standards~7. If part of PET/MRI cohort, contraindications to MRI~8. Contraindications to PSMA IV administration~9. Other unspecified reasons that, in the opinion of investigators, make the subject unsuitable for enrollment

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET/MRI (Type: EXPERIMENTAL): PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
- Multiple PET/MRI (Type: EXPERIMENTAL): Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will be invited to participate in two visits within two years, the second being an optional visit. During each visit, subjects will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. This arm will be restricted to subjects who plan to undergo focal therapy.
- PET/CT (Type: EXPERIMENTAL): PET/CT with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/CT after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. PET/CT occurs if a) an MRI can't be performed concurrently; or b) the participant already had an MRI of the abdomen/pelvis or pelvis only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval